Komori
General Meetings of Shareholders4556KAINOS Laboratories,Inc.Pharmaceuticals

Notice of Convocation of the 2026 Extraordinary General Meeting of Shareholders

To take Kainos private under the Denka Group, the company will submit to the Extraordinary General Meeting of Shareholders a proposal to consolidate 235,000 shares into 1 share, together with the associated amendments to the Articles of Incorporation. Following the share consolidation, shareholders other than the tender offeror are expected to receive cash based on ¥2,285 per share.

Worth reading
54Recurring
Scored from 3 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
235000
Consolidation of shares into 1 share (consolidation ratio)
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Extraordinary General Meeting of Shareholders
2026
May 25
Date and time24 days from this disclosure to the meeting
Matters for resolution2 items

  1. Share Consolidation

  2. Partial Amendments to the Articles of Incorporation

Shareholder Proposal

None (company proposals only)

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingExtraordinary General Meeting of Shareholders
Date and time10:00 a.m., Monday, 25 May 2026
Matters for resolutionProposal No. 1: Share Consolidation, Proposal No. 2: Partial Amendments to the Articles of Incorporation
Shareholder ProposalNone (company proposals only)
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the tender offeror was unable to acquire all of the company's shares following the tender offer, the purpose is to leave the company's shareholders as only the tender offeror and shareholders who agreed not to tender, thereby taking the company private. The company also cites enhancing corporate value through synergies with Denka and providing minority shareholders with an appropriate opportunity to sell their shares.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Extraordinary General Meeting of Shareholders | KAINOS Laboratories,Inc. (4556) timely disclosure | Komori